TY - JOUR
T1 - Prognostic Value of Hemodynamic Gain Index in Patients With Heart Failure With Reduced Ejection Fraction
AU - Chaikijurajai, Thanat
AU - Finet, J. Emanuel
AU - Engelman, Timothy
AU - Wu, Yuping
AU - Martens, Pieter
AU - Van Iterson, Erik
AU - Morales-Oyarvide, Vicente
AU - Grodin, Justin L.
AU - Tang, W. H.Wilson
N1 - Publisher Copyright:
© 2024 American College of Cardiology Foundation
PY - 2024/2
Y1 - 2024/2
N2 - Background: Assessment of functional capacity in patients with heart failure with reduced ejection fraction (HFrEF) is essential for risk stratification, and it traditionally relied on cardiopulmonary exercise testing (CPET)–derived peak oxygen consumption (peak VO2). Objectives: This study sought to investigate the prognostic value of alternative nonmetabolic exercise testing parameters in a contemporary cohort with HFrEF. Methods: Medical records of 1,067 consecutive patients with chronic HFrEF who underwent CPET from December 2012 to September 2020 were reviewed for a primary outcome that was a composite of all-cause mortality, left ventricular assist device implantation, and/or heart transplantation. Multivariable Cox regression and log-rank testing were used to determine prognostic values of various exercise testing variables. Results: The primary outcome was identified in 331 of 954 patients (34.7%) of the HFrEF cohort (median follow-up time, 946 days). After adjustment for demographics, cardiac parameters, and comorbidities, higher hemodynamic gain index (HGI) and peak rate-pressure product (RPP) were associated with greater event-free survival (adjusted HR per doubling: 0.76 and 0.36; 95% CI: 0.67-0.87 and 0.28-0.47; all P < 0.001, respectively). Moreover, HGI (area under the curve [AUC]: 0.69; 95% CI: 0.65-0.72) and peak RPP (AUC: 0.71; 95% CI: 0.68-0.74) were comparable to the standard peak VO2 (AUC: 0.70; 95% CI: 0.66-0.73; P for comparison = 0.607 and 0.393, respectively) for primary outcome discrimination. Conclusions: HGI and peak RPP show good correlation with peak VO2 in terms of prognostication and outcome discrimination in patients with HFrEF and may serve as suitable alternatives to CPET-derived prognostic variables.
AB - Background: Assessment of functional capacity in patients with heart failure with reduced ejection fraction (HFrEF) is essential for risk stratification, and it traditionally relied on cardiopulmonary exercise testing (CPET)–derived peak oxygen consumption (peak VO2). Objectives: This study sought to investigate the prognostic value of alternative nonmetabolic exercise testing parameters in a contemporary cohort with HFrEF. Methods: Medical records of 1,067 consecutive patients with chronic HFrEF who underwent CPET from December 2012 to September 2020 were reviewed for a primary outcome that was a composite of all-cause mortality, left ventricular assist device implantation, and/or heart transplantation. Multivariable Cox regression and log-rank testing were used to determine prognostic values of various exercise testing variables. Results: The primary outcome was identified in 331 of 954 patients (34.7%) of the HFrEF cohort (median follow-up time, 946 days). After adjustment for demographics, cardiac parameters, and comorbidities, higher hemodynamic gain index (HGI) and peak rate-pressure product (RPP) were associated with greater event-free survival (adjusted HR per doubling: 0.76 and 0.36; 95% CI: 0.67-0.87 and 0.28-0.47; all P < 0.001, respectively). Moreover, HGI (area under the curve [AUC]: 0.69; 95% CI: 0.65-0.72) and peak RPP (AUC: 0.71; 95% CI: 0.68-0.74) were comparable to the standard peak VO2 (AUC: 0.70; 95% CI: 0.66-0.73; P for comparison = 0.607 and 0.393, respectively) for primary outcome discrimination. Conclusions: HGI and peak RPP show good correlation with peak VO2 in terms of prognostication and outcome discrimination in patients with HFrEF and may serve as suitable alternatives to CPET-derived prognostic variables.
KW - cardiopulmonary exercise testing
KW - heart failure with reduced ejection fraction
KW - hemodynamic gain index
KW - prognosis
KW - rate-pressure product
UR - http://www.scopus.com/inward/record.url?scp=85183526607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85183526607&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2023.05.005
DO - 10.1016/j.jchf.2023.05.005
M3 - Article
C2 - 37318421
AN - SCOPUS:85183526607
SN - 2213-1779
VL - 12
SP - 261
EP - 271
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 2
ER -